Wednesday, September 28, 2016 5:12:38 PM
Mar 23, 2016 11.09 12.64 10.65 12.48 16,786,795
Mar 22, 2016 9.53 10.46 9.35 10.01 4,519,850
Mar 21, 2016 8.61 10.09 8.57 9.71 6,452,212
Mar 18, 2016 8.95 9.16 8.11 8.70 3,396,110
Mar 17, 2016 9.38 9.75 8.50 8.85 5,719,331
Mar 16, 2016 8.53 10.25 8.50 9.38 20,578,982
Mar 15, 2016 8.15 9.10 6.44 8.94 39,443,694
Mar 14, 2016 1.54 1.90 1.51 1.68 449,792
Mar 11, 2016 1.54 1.57 1.40 1.53 279,189
Mar 10, 2016 1.56 1.63 1.44 1.49 190,279
Mar 9, 2016 1.63 1.63 1.37 1.54 543,353
Mar 8, 2016 1.71 1.77 1.60 1.60 277,268
Mar 7, 2016 1.83 1.93 1.65 1.69 676,042
Mar 4, 2016 1.91 1.96 1.85 1.86 374,237
Mar 3, 2016 1.91 1.95 1.89 1.91 148,745
Mar 2, 2016 1.83 2.00 1.80 1.94 415,844
Mar 1, 2016 2.11 2.12 1.70 1.89 1,045,080
Feb 29, 2016 2.17 2.32 2.10 2.14 809,576
Feb 26, 2016 2.15 2.20 2.12 2.19 336,807
Feb 25, 2016 2.20 2.24 2.09 2.13 391,789
Feb 24, 2016 2.20 2.40 2.12 2.15 613,922
Feb 23, 2016 2.48 2.48 1.99 2.27 1,091,318
Feb 22, 2016 2.44 2.51 2.22 2.37 1,507,999
Feb 19, 2016 2.00 2.30 1.98 2.18 1,362,110
Feb 18, 2016
Recent PTN News
- Palatin Receives Notice of Non-Compliance from NYSE American • PR Newswire (US) • 10/07/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2024 12:15:23 PM
- Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones • PR Newswire (US) • 10/01/2024 11:30:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/30/2024 08:31:04 PM
- Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results • PR Newswire (US) • 09/26/2024 11:30:00 AM
- Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones • PR Newswire (US) • 09/09/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 08:35:29 PM
- FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED) • PR Newswire (US) • 08/28/2024 11:30:00 AM
- First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity • PR Newswire (US) • 08/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:01:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:31:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:31:01 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/25/2024 08:46:11 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 07/17/2024 03:14:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:32:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:32:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:31:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:31:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:31:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:31:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:31:16 PM
- Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds • PR Newswire (US) • 06/21/2024 12:00:00 PM
- Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED) • PR Newswire (US) • 06/20/2024 11:30:00 AM
- Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity • PR Newswire (US) • 06/12/2024 11:30:00 AM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM